Press Releases
Back to Previous Page
 


News Release

April 4, 2019
Your Contact:
karen.tiano@emdmillipore.com
Phone: +1 978 495 0093


MilliporeSigma Recognized with INTERPHEX Exhibitor Award for Best New Product

  • Company wins for first-of-its-kind, single-use tangential flow filtration capsule used in ADC and monoclonal antibody bioprocessing

Burlington, Massachusetts, April 4, 2019 — MilliporeSigma today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next- generation bioprocessing. MilliporeSigma’s Pellicon® Capsule with Ultracel® Membrane has been recognized for Best New Product.

“This recognition is for an innovation that enables biomanufacturers to realize the benefits of process intensification throughout the entire bioprocess,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “We will continue to revolutionize drug manufacturing with solutions that set the standard for improvements in process efficiency, simplified plant operations and consistency in manufacturing.”

MilliporeSigma’s Pellicon® Capsule with Ultracel® Membrane is the first-of-its-kind single-use tangential flow filtration capsule for bioprocessing of antibody-drug conjugates and monoclonal antibodies. The capsule reduces the risk of product cross-contamination, as well as exposure to highly toxic compounds during both processing and disassembly. The self-contained design is ideal for the safe and easy removal of the entire single-use TFF flow path immediately after product recovery, optimizing product changeover efficiency and saving time. The device requires no cleaning validation requirements, thereby reducing its footprint in the manufacturing environment which ultimately leads to increased plant productivity and process flexibility with the added benefit of reduced contamination risks.

MilliporeSigma works with drug manufacturers to help bring life-enhancing drug therapies to market, faster. Its innovative technologies improve productivity, lower risks, reduce costs and ensure drug safety.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.